236 related articles for article (PubMed ID: 26265617)
1. Reduction of Glucose Metabolism in Olfactory Bulb is an Earlier Alzheimer's Disease-related Biomarker in 5XFAD Mice.
Xiao NA; Zhang J; Zhou M; Wei Z; Wu XL; Dai XM; Zhu YG; Chen XC
Chin Med J (Engl); 2015 Aug; 128(16):2220-7. PubMed ID: 26265617
[TBL] [Abstract][Full Text] [Related]
2. Butyrylcholinesterase-knockout reduces fibrillar β-amyloid and conserves
DeBay DR; Reid GA; Macdonald IR; Mawko G; Burrell S; Martin E; Bowen CV; Darvesh S
Brain Res; 2017 Sep; 1671():102-110. PubMed ID: 28729192
[TBL] [Abstract][Full Text] [Related]
3. Early detection of cerebral glucose uptake changes in the 5XFAD mouse.
Macdonald IR; DeBay DR; Reid GA; O'Leary TP; Jollymore CT; Mawko G; Burrell S; Martin E; Bowen CV; Brown RE; Darvesh S
Curr Alzheimer Res; 2014; 11(5):450-60. PubMed ID: 24801216
[TBL] [Abstract][Full Text] [Related]
4. Age- and Brain Region-Specific Changes of Glucose Metabolic Disorder, Learning, and Memory Dysfunction in Early Alzheimer's Disease Assessed in APP/PS1 Transgenic Mice Using
Li XY; Men WW; Zhu H; Lei JF; Zuo FX; Wang ZJ; Zhu ZH; Bao XJ; Wang RZ
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27763550
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of 10-minute post-injection 11C-PiB PET and its correlation with 18F-FDG PET in older adults who are cognitively healthy, mildly impaired, or with probable Alzheimer's disease.
Carneiro CG; Faria DP; Coutinho AM; Ono CR; Duran FLS; da Costa NA; Garcez AT; da Silveira PS; Forlenza OV; Brucki SMD; Nitrini R; Busatto G; Buchpiguel CA
Braz J Psychiatry; 2022 Aug; 44(5):495-506. PubMed ID: 36420910
[TBL] [Abstract][Full Text] [Related]
6. In vivo evaluation of amyloid deposition and brain glucose metabolism of 5XFAD mice using positron emission tomography.
Rojas S; Herance JR; Gispert JD; Abad S; Torrent E; Jiménez X; Pareto D; Perpiña U; Sarroca S; Rodríguez E; Ortega-Aznar A; Sanfeliu C
Neurobiol Aging; 2013 Jul; 34(7):1790-8. PubMed ID: 23402900
[TBL] [Abstract][Full Text] [Related]
7. Cerebral Glucose Metabolism Assessment in Rat Models of Alzheimer's Disease: An 18F-FDG-PET Study.
Lu Y; Ren J; Cui S; Chen J; Huang Y; Tang C; Shan B; Nie B; Xinsheng L
Am J Alzheimers Dis Other Demen; 2016 Jun; 31(4):333-40. PubMed ID: 26631686
[TBL] [Abstract][Full Text] [Related]
8. [
Maruyama H; Gomi M; Lwin TT; Yoneyama A; Sasaki T
Ann Nucl Med; 2024 Feb; 38(2):120-130. PubMed ID: 37921921
[TBL] [Abstract][Full Text] [Related]
9. Increased regional cerebral glucose uptake in an APP/PS1 model of Alzheimer's disease.
Poisnel G; Hérard AS; El Tannir El Tayara N; Bourrin E; Volk A; Kober F; Delatour B; Delzescaux T; Debeir T; Rooney T; Benavides J; Hantraye P; Dhenain M
Neurobiol Aging; 2012 Sep; 33(9):1995-2005. PubMed ID: 22079157
[TBL] [Abstract][Full Text] [Related]
10. Thiamine diphosphate reduction strongly correlates with brain glucose hypometabolism in Alzheimer's disease, whereas amyloid deposition does not.
Sang S; Pan X; Chen Z; Zeng F; Pan S; Liu H; Jin L; Fei G; Wang C; Ren S; Jiao F; Bao W; Zhou W; Guan Y; Zhang Y; Shi H; Wang Y; Yu X; Wang Y; Zhong C
Alzheimers Res Ther; 2018 Mar; 10(1):26. PubMed ID: 29490669
[TBL] [Abstract][Full Text] [Related]
11. Hippocampal glucose uptake as a surrogate of metabolic change of microglia in Alzheimer's disease.
Choi H; Choi Y; Lee EJ; Kim H; Lee Y; Kwon S; Hwang DW; Lee DS;
J Neuroinflammation; 2021 Aug; 18(1):190. PubMed ID: 34465358
[TBL] [Abstract][Full Text] [Related]
12.
Franke TN; Irwin C; Bayer TA; Brenner W; Beindorff N; Bouter C; Bouter Y
Front Med (Lausanne); 2020; 7():529. PubMed ID: 33043029
[TBL] [Abstract][Full Text] [Related]
13. Intact olfactory memory in the 5xFAD mouse model of Alzheimer's disease from 3 to 15 months of age.
O'Leary TP; Stover KR; Mantolino HM; Darvesh S; Brown RE
Behav Brain Res; 2020 Sep; 393():112731. PubMed ID: 32522622
[TBL] [Abstract][Full Text] [Related]
14. Amyloid-β deposition and olfactory dysfunction in an Alzheimer's disease model.
Wu N; Rao X; Gao Y; Wang J; Xu F
J Alzheimers Dis; 2013; 37(4):699-712. PubMed ID: 23948910
[TBL] [Abstract][Full Text] [Related]
15. Quantitative Brain Positron Emission Tomography in Female 5XFAD Alzheimer Mice: Pathological Features and Sex-Specific Alterations.
Bouter C; Irwin C; Franke TN; Beindorff N; Bouter Y
Front Med (Lausanne); 2021; 8():745064. PubMed ID: 34901060
[TBL] [Abstract][Full Text] [Related]
16. Nocturnal Hypoxia and Sleep Fragmentation May Drive Neurodegenerative Processes: The Compared Effects of Obstructive Sleep Apnea Syndrome and Periodic Limb Movement Disorder on Alzheimer's Disease Biomarkers.
Fernandes M; Chiaravalloti A; Manfredi N; Placidi F; Nuccetelli M; Izzi F; Camedda R; Bernardini S; Schillaci O; Mercuri NB; Liguori C
J Alzheimers Dis; 2022; 88(1):127-139. PubMed ID: 35570484
[TBL] [Abstract][Full Text] [Related]
17. The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function.
Dowling NM; Johnson SC; Gleason CE; Jagust WJ;
Neuroimage; 2015 Jan; 105():357-68. PubMed ID: 25450107
[TBL] [Abstract][Full Text] [Related]
18. Hypothalamic dysfunction is related to sleep impairment and CSF biomarkers in Alzheimer's disease.
Liguori C; Chiaravalloti A; Nuccetelli M; Izzi F; Sancesario G; Cimini A; Bernardini S; Schillaci O; Mercuri NB; Fabio P
J Neurol; 2017 Nov; 264(11):2215-2223. PubMed ID: 28900724
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Effects of Aripiprazole in the 5xFAD Alzheimer's Disease Mouse Model.
Jeong YJ; Son Y; Park HJ; Oh SJ; Choi JY; Ko YG; Lee HJ
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502282
[TBL] [Abstract][Full Text] [Related]
20. Correlation Between Brain 18F-AV45 and 18F-FDG PET Distribution Characteristics and Cognitive Function in Patients with Mild and Moderate Alzheimer's Disease.
Jing J; Zhang F; Zhao L; Xie J; Chen J; Zhong R; Zhang Y; Dong C
J Alzheimers Dis; 2021; 79(3):1317-1325. PubMed ID: 33427748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
